Skip to main content
Top
Published in: Clinical Rheumatology 6/2016

01-06-2016 | Original Article

Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study

Authors: M.A. Quintana-Duque, F. Rondon-Herrera, R.D Mantilla, E. Calvo-Paramo, J.J. Yunis, A. Varela-Nariño, J.F. Restrepo, A. Iglesias-Gamarra

Published in: Clinical Rheumatology | Issue 6/2016

Login to get access

Abstract

The objective of the study is to find predictors of remission, radiographic progression (RP), and erosive disease in a cohort of patients with early onset rheumatoid arthritis (EORA) that followed a therapeutic protocol aiming at remission, in a real world tight-control setting. EORA patients were enrolled in a 3-year follow-up study. Clinical, biological, immunogenetic, and radiographical data were analyzed. Radiographs were scored according to Sharp–van der Heijde (SvdH) method. RP was defined by an increase of 3 units in 36 months. Remission was defined as DAS28 <2.6. A stepwise multiple logistic regression model was used to identify independent predictors of the three target outcomes. One hundred twenty-nine patients were included. Baseline disease activity was high. Significant overall improvement was observed, but only 33.3 % achieved remission. At 36 month, 50.4 % (65) of patients showed erosions. RP was observed in 62.7 % (81) of cases. Statistical analysis showed that baseline SvdH score was the only predictive factor associated with the three outcomes evaluated. Lower HAQ-DI and absence of autoantibodies were predictive of remission. Higher levels of ESR and presence of erosions at entry were predictive of RP. Independent baseline predictors of incident erosive disease were anti-CCP and RF positivity, symptom duration at baseline >3 months, and presence of HLA-DRB1 shared epitope. Radiographic damage at baseline was the main predictor of outcomes. Autoantibodies, HAQ and ESR at baseline, symptom duration before diagnosis, and HLA-DRB1 status had influence on clinical course and development of structural joint damage in Colombian RA patients.
Literature
1.
go back to reference Pincus T, Callahan LF, Sale WG et al (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864CrossRefPubMed Pincus T, Callahan LF, Sale WG et al (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864CrossRefPubMed
2.
go back to reference Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42:1209–1218CrossRefPubMed Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 42:1209–1218CrossRefPubMed
3.
go back to reference Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–18CrossRefPubMed Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–18CrossRefPubMed
4.
go back to reference Mottonen T, Hannonen P, Korpela M et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898CrossRefPubMed Mottonen T, Hannonen P, Korpela M et al (2002) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898CrossRefPubMed
5.
go back to reference St. Clair EW, van der Heijde DMFM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–43CrossRefPubMed St. Clair EW, van der Heijde DMFM, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–43CrossRefPubMed
6.
go back to reference Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–90CrossRefPubMed Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–90CrossRefPubMed
7.
go back to reference Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37CrossRefPubMed Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37CrossRefPubMed
8.
go back to reference Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406–15CrossRefPubMed Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146:406–15CrossRefPubMed
9.
go back to reference Machold KP, Stamm TA, Eberl GJ et al (2002) Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278PubMed Machold KP, Stamm TA, Eberl GJ et al (2002) Very recent onset arthritis - clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278PubMed
10.
go back to reference MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K et al (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–7CrossRefPubMed MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K et al (2000) Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 43:30–7CrossRefPubMed
11.
go back to reference Lee YH, Ji JD, Song GG (2007) Tumor necrosis factor-alpha promoter −308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol 1:43–9 Lee YH, Ji JD, Song GG (2007) Tumor necrosis factor-alpha promoter −308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis. J Rheumatol 1:43–9
12.
go back to reference Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S et al (2009) Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 36:266–272CrossRefPubMed Syversen SW, Goll GL, van der Heijde D, Landewe R, Gaarder PI, Odegard S et al (2009) Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 36:266–272CrossRefPubMed
13.
go back to reference Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H et al (2002) Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 46:913–920CrossRefPubMed Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H et al (2002) Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 46:913–920CrossRefPubMed
14.
go back to reference Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O et al (2004) Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 63:675–80CrossRefPubMedPubMedCentral Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O et al (2004) Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 63:675–80CrossRefPubMedPubMedCentral
15.
go back to reference Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D et al (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 46:342–9CrossRef Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D et al (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 46:342–9CrossRef
16.
go back to reference Eberhardt K, Fex E (1998) Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 37:1324–9CrossRefPubMed Eberhardt K, Fex E (1998) Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 37:1324–9CrossRefPubMed
17.
go back to reference van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–71CrossRefPubMed van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60:2262–71CrossRefPubMed
18.
go back to reference Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) For the BARFOT study group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66:46–52CrossRefPubMedPubMedCentral Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) For the BARFOT study group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66:46–52CrossRefPubMedPubMedCentral
19.
go back to reference Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P et al (2012) Early Rheumatoid Arthritis Study (ERAS). Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 51:169–75CrossRef Jayakumar K, Norton S, Dixey J, James D, Gough A, Williams P et al (2012) Early Rheumatoid Arthritis Study (ERAS). Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 51:169–75CrossRef
20.
go back to reference Kroot E-J, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835CrossRefPubMed Kroot E-J, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835CrossRefPubMed
21.
go back to reference Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089CrossRefPubMedPubMedCentral Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089CrossRefPubMedPubMedCentral
22.
go back to reference Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman A et al (1996) A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 24:471–476CrossRef Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman A et al (1996) A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 24:471–476CrossRef
23.
go back to reference Jansen MA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927CrossRefPubMedPubMedCentral Jansen MA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA (2001) Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924–927CrossRefPubMedPubMedCentral
24.
go back to reference Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736–1743CrossRefPubMed Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736–1743CrossRefPubMed
25.
go back to reference Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 26:1111–8CrossRefPubMed Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I et al (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 26:1111–8CrossRefPubMed
26.
go back to reference Lindqvist E, Jonsson K, Saxne T, Eberhardt K (2003) Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62:611–6CrossRefPubMedPubMedCentral Lindqvist E, Jonsson K, Saxne T, Eberhardt K (2003) Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62:611–6CrossRefPubMedPubMedCentral
27.
go back to reference Wolfe F, Sharp JT (1998) Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 41:1571–82CrossRefPubMed Wolfe F, Sharp JT (1998) Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 41:1571–82CrossRefPubMed
28.
go back to reference Contreras-Yáñez I, Rull-Gabayet M, Vázquez-Lamadrid J, Pascual-Ramos V (2011) Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Eur J Radiol 79:e52–7CrossRefPubMed Contreras-Yáñez I, Rull-Gabayet M, Vázquez-Lamadrid J, Pascual-Ramos V (2011) Radiographic outcome in Hispanic early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs. Eur J Radiol 79:e52–7CrossRefPubMed
29.
go back to reference Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–9CrossRefPubMedPubMedCentral Rönnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–9CrossRefPubMedPubMedCentral
30.
go back to reference Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA (2002) Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 61:351–3CrossRefPubMedPubMedCentral Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA (2002) Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 61:351–3CrossRefPubMedPubMedCentral
31.
go back to reference Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D et al (1994) Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 37:1166–70CrossRefPubMed Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D et al (1994) Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 37:1166–70CrossRefPubMed
32.
go back to reference van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GM, D’Amoro J et al (1991) Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Arthritis Rheum 34:822–30CrossRefPubMed van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GM, D’Amoro J et al (1991) Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Arthritis Rheum 34:822–30CrossRefPubMed
33.
go back to reference Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50:400–12CrossRefPubMed Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50:400–12CrossRefPubMed
34.
go back to reference Reneses S, González-Escribano MF, Fernández-Suárez A, Pestana L, Davila B, Wichmann I et al (2009) The value of HLA-DRB1 shared epitope, −308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis. J Rheumatol 36:1143–9CrossRefPubMed Reneses S, González-Escribano MF, Fernández-Suárez A, Pestana L, Davila B, Wichmann I et al (2009) The value of HLA-DRB1 shared epitope, −308 tumor necrosis factor-alpha gene promoter polymorphism, rheumatoid factor, anti-citrullinated peptide antibodies, and early erosions for predicting radiological outcome in recent-onset rheumatoid arthritis. J Rheumatol 36:1143–9CrossRefPubMed
35.
go back to reference Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE et al (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 67:358–63CrossRefPubMedPubMedCentral Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE et al (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis 67:358–63CrossRefPubMedPubMedCentral
36.
go back to reference Janssens AC, Steyerberg EW, Jiang Y, Habbema JD, Van Duijn CM, Criswell LA (2006) Value of the HLA-DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile. J Rheumatol 33:2383–9PubMed Janssens AC, Steyerberg EW, Jiang Y, Habbema JD, Van Duijn CM, Criswell LA (2006) Value of the HLA-DRB1 shared epitope for predicting radiographic damage in rheumatoid arthritis depends on the individual patient risk profile. J Rheumatol 33:2383–9PubMed
37.
go back to reference Rojas-Villarraga A, Diaz FJ, Calvo-Páramo E, Salazar JC, Iglesias-Gamarra A, Mantilla RD et al (2009) Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun 32:64–9CrossRefPubMed Rojas-Villarraga A, Diaz FJ, Calvo-Páramo E, Salazar JC, Iglesias-Gamarra A, Mantilla RD et al (2009) Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun 32:64–9CrossRefPubMed
38.
go back to reference Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 70:1292–5CrossRefPubMedPubMedCentral Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 70:1292–5CrossRefPubMedPubMedCentral
39.
go back to reference Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 72:858–62CrossRefPubMedPubMedCentral Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R et al (2013) Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 72:858–62CrossRefPubMedPubMedCentral
40.
go back to reference Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA et al (2010) Tumour necrosis factor alpha -308G- > A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 69:1022–8CrossRefPubMed Pavy S, Toonen EJ, Miceli-Richard C, Barrera P, van Riel PL, Criswell LA et al (2010) Tumour necrosis factor alpha -308G- > A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 69:1022–8CrossRefPubMed
41.
go back to reference Aranda F, Perés Wingeyer SD, Schneeberger E, Valerio M, Saint Martin E, Dal Pra F, et al. (2014) The −308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients. Int J Rheum Dis. doi: 10.1111/1756-185X.12343. Aranda F, Perés Wingeyer SD, Schneeberger E, Valerio M, Saint Martin E, Dal Pra F, et al. (2014) The −308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients. Int J Rheum Dis. doi: 10.​1111/​1756-185X.​12343.
42.
go back to reference Bridges SL Jr, Causey ZL, Burgos PI, Huynh BQ, Hughes LB, Danila MI et al (2010) Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res (Hoboken) 62:624–31CrossRef Bridges SL Jr, Causey ZL, Burgos PI, Huynh BQ, Hughes LB, Danila MI et al (2010) Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res (Hoboken) 62:624–31CrossRef
43.
go back to reference van Nies JA, van Steenbergen HW, Krabben A, Stomp W, Huizinga TW, Reijnierse M et al (2015) Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. Ann Rheum Dis 74(5):883–9CrossRefPubMed van Nies JA, van Steenbergen HW, Krabben A, Stomp W, Huizinga TW, Reijnierse M et al (2015) Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. Ann Rheum Dis 74(5):883–9CrossRefPubMed
44.
go back to reference Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D et al (2009) Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 68:1535–40CrossRefPubMed Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D et al (2009) Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 68:1535–40CrossRefPubMed
45.
go back to reference Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, van der Heijde D (2015) Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther 17:133CrossRefPubMedPubMedCentral Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, van der Heijde D (2015) Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther 17:133CrossRefPubMedPubMedCentral
Metadata
Title
Predictors of remission, erosive disease and radiographic progression in a Colombian cohort of early onset rheumatoid arthritis: a 3-year follow-up study
Authors
M.A. Quintana-Duque
F. Rondon-Herrera
R.D Mantilla
E. Calvo-Paramo
J.J. Yunis
A. Varela-Nariño
J.F. Restrepo
A. Iglesias-Gamarra
Publication date
01-06-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3246-5

Other articles of this Issue 6/2016

Clinical Rheumatology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.